Blog
RSS FeedPosted by Michael Wonder on 17 Dec 2024
ICER publishes final evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
16 December 2024 - Independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for ...
Posted by Michael Wonder on 01 Nov 2024
ICER publishes evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
31 October 2024 - Current evidence suggests that tabelecleucel provides a substantial net health benefit when compared to usual care; ...
Posted by Michael Wonder on 12 Sep 2024
ICER releases draft evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
12 September 2024 - Public comment period now open until 8 October 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 02 May 2024
ICER to assess treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
2 May 2024 - Report will be subject of New England CEPAC meeting in November 2024; draft scoping document open ...
Posted by Michael Wonder on 11 May 2021
ICER publishes final evidence report and policy recommendations on therapies for multiple myeloma
11 May 2021 - Independent appraisal committee unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel ...
Posted by Michael Wonder on 05 Apr 2021
ICER publishes evidence report on therapies for multiple myeloma
5 April 2021 - The evidence suggests CAR-Ts ide-cel and cilta-cel both have the potential to help patients live substantially ...
Posted by Michael Wonder on 17 Dec 2020
ICER publishes final evidence report and policy recommendations on new therapies for bladder cancer
17 December 2020 - Independent appraisal committee determines current evidence is adequate to demonstrate that nadofaragene firadenovec and oportuzumab monatox ...
Posted by Michael Wonder on 31 Aug 2020
ICER to assess CAR-T cell therapies for multiple myeloma
31 August 2020 - Report will be subject of Midwest CEPAC meeting in April 2021; open input now being accepted until ...
Posted by Michael Wonder on 06 Aug 2019
ICER seeks public comment on proposed methods adaptations for assessments of potential cures and other transformative therapies
6 August 2019 - Proposed adaptations help manage increased uncertainty, capture new value dimensions for appraisal committee voting, and adopt a ...
Posted by Michael Wonder on 26 Nov 2018
Novartis CEO says four factors can help with pricing and payment of life saving cell and gene therapies
26 November 2018 - The new therapies are challenging the traditional model for paying for medical treatment, and the industry is ...
Posted by Michael Wonder on 24 Mar 2018
ICER final report on CAR-T therapies highlights need for systemwide changes to ensure affordability and access to innovative, one-time therapies
23 March 2018 - Policy recommendations highlight that even though the pricing of current CAR-T therapies aligns with patient benefit ...
Posted by Michael Wonder on 18 Feb 2018
ICER report finds costs of approved CAR-T therapies align with clinical benefit
15 February 2018 - Report will be subject to public deliberation during CTAF meeting on 2 March 2018. ...
Posted by Michael Wonder on 20 Dec 2017
Institute for Clinical and Economic Review releases draft evidence report on CAR-T therapy for B-cell cancers
19 December 2017 - Public comment period open now until 24 January; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 09 Aug 2017
Institute for Clinical and Economic Review posts draft scoping document on CAR-T therapies for public comment
9 August 2017 - Report expected to review axicabtagene ciloleucel and tisagenlecleucel-t, first CAR-T therapies submitted for FDA. ...
Posted by Michael Wonder on 19 Jul 2017
Institute for Clinical and Economic Review to evaluate CAR-T therapies in upcoming report
19 July 2017 - Report tentatively expected to review axicabtagene ciloleucel (Kite Pharmaceuticals) and tisagenlecleucel-t (Novartis). ...